famotidine has been researched along with Cardiomyopathies, Primary in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects." | 1.48 | Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model. ( Allakonda, L; Kondru, SK; Konduri, P; Potnuri, AG, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kondru, SK | 1 |
| Potnuri, AG | 1 |
| Allakonda, L | 1 |
| Konduri, P | 1 |
1 other study available for famotidine and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.
Topics: Animals; Apoptosis; Cardiomyopathies; Doxorubicin; Famotidine; Histamine H2 Antagonists; Male; Muscl | 2018 |